This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
A GLP-1 receptor agonist that mimics the body's natural satiety hormone — reducing appetite, regulating blood sugar, and producing the most clinically documented weight loss of any peptide available for research.
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone produced in the gut after eating. GLP-1 naturally signals satiety to the brain, slows gastric emptying, and stimulates insulin release in response to blood sugar. Semaglutide replicates this signaling with a modified molecular structure that extends its half-life to approximately one week — enabling once-weekly dosing.
It gained FDA approval as Ozempic (diabetes management, 2017) and later Wegovy (weight loss, 2021) — marking the first time a GLP-1 agonist received approval specifically for chronic weight management. Clinical trials showed average body weight reduction of approximately 15% over 68 weeks — results unprecedented in the history of weight loss pharmacology.
Semaglutide works through multiple pathways: direct GLP-1 receptor activation in the hypothalamus reduces appetite and food cravings; slowing gastric emptying extends the feeling of fullness; and improved insulin sensitivity addresses the metabolic dysfunction common in obesity. The combination produces sustained, progressive weight loss without stimulant-based mechanisms.
The STEP trial program showed average body weight reduction of 14.9% over 68 weeks — the most clinically significant weight loss result ever published for a non-surgical intervention.
GLP-1 receptor activation in the hypothalamus directly reduces hunger signals and food reward — users report changes in cravings and relationship with food, not just willpower-mediated restriction.
Stimulates insulin release in a glucose-dependent manner and suppresses glucagon — improving fasting glucose and HbA1c without hypoglycemia risk in non-diabetic users.
The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in overweight/obese individuals without diabetes — a landmark finding beyond weight loss.
A half-life of approximately one week enables weekly subcutaneous injection — the most convenient dosing schedule of any GLP-1 agonist in this class.
Semaglutide has more published Phase 3 human trial data than any other weight loss peptide — a depth of evidence that distinguishes it from earlier-generation compounds.
Semaglutide is administered subcutaneously once weekly. A gradual dose escalation schedule is critical for tolerability — starting too high causes significant nausea. Most protocols follow the Wegovy titration schedule: start at 0.25 mg/week and increase by 0.25 mg every 4 weeks.
| Week | Dose | Notes |
|---|---|---|
| Weeks 1–4 | 0.25 mg weekly | Initiation dose — not therapeutic, tolerance building |
| Weeks 5–8 | 0.5 mg weekly | First therapeutic dose |
| Weeks 9–12 | 1.0 mg weekly | — |
| Weeks 13–16 | 1.7 mg weekly | — |
| Week 17+ | 2.4 mg weekly | Maintenance dose (max weight loss dose per Wegovy labeling) |
| Route | Subcutaneous — abdomen, upper thigh, or upper arm | |
The flagship STEP 1 trial (N=1961, 68 weeks) showed 14.9% average body weight reduction vs 2.4% placebo — setting the benchmark for pharmacological weight loss interventions.
In overweight/obese adults without diabetes (N=17,604), semaglutide reduced major adverse cardiovascular events by 20% — establishing cardiovascular benefit independent of diabetes status.
The SUSTAIN trial series (8 trials) established semaglutide's superior HbA1c reduction and weight loss versus older GLP-1 agonists and other diabetes medications.
Two-year data from STEP 5 showed maintained weight loss of 15.2% — confirming that semaglutide's effects are durable with continued weekly administration.
GLP-1 protocols are frequently combined with recovery peptides to preserve muscle mass during caloric restriction and support body composition during weight loss.
Ozempic and Wegovy are branded, FDA-approved prescription pharmaceutical products. Research semaglutide is the same molecule — same amino acid sequence, same pharmacological mechanism — produced and sold for research purposes only, not as a pharmaceutical drug. Third-party COA verification of identity, purity, and concentration is essential to confirm what you're actually receiving.
GLP-1 receptors in the gut drive the most common side effects (nausea, vomiting, diarrhea). Slow titration allows receptor accommodation to reduce these effects. Starting at the full therapeutic dose causes severe nausea in most users — gradual escalation is not optional, it's protocol.
Weight typically returns when semaglutide is discontinued, as the appetite suppression is pharmacologically maintained. The STEP 4 withdrawal trial showed progressive weight regain over 52 weeks after stopping. Most clinicians treating obesity consider it a long-term medication, not a short course.
Tirzepatide adds GIP receptor agonism on top of GLP-1, producing greater average weight loss (20–22% vs ~15% for semaglutide). For maximum weight loss efficacy, tirzepatide has the edge in head-to-head comparisons. Both are once-weekly subcutaneous peptides with similar side effect profiles.
Semaglutide is sold for research purposes only. While it is FDA-approved in branded pharmaceutical form (Ozempic, Wegovy), research peptide semaglutide is not an FDA-approved drug and should not be used as a substitute for physician-prescribed treatment. This information is educational and does not constitute medical advice. Consult a qualified healthcare professional before considering any GLP-1 protocol.
Availability Notice: GLP-1 receptor agonists including semaglutide currently require physician coordination and are available by waitlist only. Join below to be notified when your protocol is ready.
GLP-1 protocols require physician review and compounding pharmacy coordination. Submit your intake — our team will contact you when your protocol is confirmed and ready to ship.
Join the WaitlistMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.